Hannah's doctor prescribed Saxenda - part of a group of drugs known ... But while Hannah hasn't found the drug to be useful for weight loss, six months on, she's more than willing to keep paying ...

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide.

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.